Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Southeastern Gynecologic Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT00897039
- Locations
- 🇺🇸
Southeastern Gynecologic Oncology, LLP - Northside, Atlanta, Georgia, United States
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Southeastern Gynecologic Oncology
- Target Recruit Count
- 40
- Registration Number
- NCT00466986
- Locations
- 🇺🇸
Southeastern Gynecologic Oncology, Atlanta, Georgia, United States
DOXIL for Consolidation Therapy in Ovarian Cancer.
Phase 2
Completed
- Conditions
- Ovarian Neoplasm
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Southeastern Gynecologic Oncology
- Target Recruit Count
- 45
- Registration Number
- NCT00248248
- Locations
- 🇺🇸
Southeastern Gynecologic Oncology, Atlanta, Georgia, United States